Cytokinetics, Incorporated Forecast, price target & analysts
Cytokinetics, Incorporated Target price 2026 - Analyst rating & recommendation
Cytokinetics, Incorporated Classifications & Recommendation
Cytokinetics, Incorporated Price Target
| Target Price | $110.16 |
| Price | $65.66 |
| Potential |
67.77%
register free of charge
|
| Number of Estimates | 22 |
|
22 Analysts have issued a price target Cytokinetics, Incorporated 2027 .
The average Cytokinetics, Incorporated target price is $110.16.
This is
67.77%
register free of charge
$153.30
133.48%
register free of charge
$85.85
30.75%
register free of charge
|
|
| A rating was issued by 28 analysts: 25 Analysts recommend Cytokinetics, Incorporated to buy, 3 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Cytokinetics, Incorporated stock has an average upside potential 2027 of
67.77%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 88.04 | 152.76 |
| 376.66% | 73.51% | |
| EBITDA Margin | -683.93% | -481.23% |
| 76.02% | 29.64% | |
| Net Margin | -891.59% | -566.85% |
| 72.07% | 36.42% |
24 Analysts have issued a sales forecast Cytokinetics, Incorporated 2026 . The average Cytokinetics, Incorporated sales estimate is
This results in the following potential growth metrics:
11 Analysts have issued an Cytokinetics, Incorporated EBITDA forecast 2026. The average Cytokinetics, Incorporated EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
24 Cytokinetics, Incorporated Analysts have issued a net profit forecast 2026. The average Cytokinetics, Incorporated net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -6.54 | -6.24 |
| 24.33% | 4.59% | |
| P/E | negative | |
| EV/Sales | 59.63 |
24 Analysts have issued a Cytokinetics, Incorporated forecast for earnings per share. The average Cytokinetics, Incorporated EPS is
This results in the following potential growth metrics and future valuations:
Cytokinetics, Incorporated...
Current Cytokinetics, Incorporated Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Aug 31 2026 |
| JP Morgan |
Locked
➜
Locked
|
Locked | Aug 13 2026 |
| Barclays |
Locked
➜
Locked
|
Locked | Aug 13 2026 |
| Truist Securities |
Locked
➜
Locked
|
Locked | Aug 10 2026 |
| Needham |
Locked
➜
Locked
|
Locked | Aug 07 2026 |
| RBC Capital |
Locked
➜
Locked
|
Locked | Aug 07 2026 |
| Citizens |
Locked
➜
Locked
|
Locked | Aug 07 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Aug 31 2026 |
|
Locked
JP Morgan:
Locked
➜
Locked
|
Aug 13 2026 |
|
Locked
Barclays:
Locked
➜
Locked
|
Aug 13 2026 |
|
Locked
Truist Securities:
Locked
➜
Locked
|
Aug 10 2026 |
|
Locked
Needham:
Locked
➜
Locked
|
Aug 07 2026 |
|
Locked
RBC Capital:
Locked
➜
Locked
|
Aug 07 2026 |
|
Locked
Citizens:
Locked
➜
Locked
|
Aug 07 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
